Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

1999 AAPS news: Lilly studies PK interactions between LY-335979 and doxorubicin in patients

Nov. 22, 1999

OC144-093: clinical pharmacokinetics and safety after i.v. and oral dosing

Nov. 22, 1999

Phase I clinical trial initiated with Xcytrin for treatment of childhood gliomas

Nov. 22, 1999

Korean researchers describe efforts to develop colon-specific 5-FU prodrug

Nov. 22, 1999

Vical's cancer gene therapies profiled at chemotherapy meeting

Nov. 22, 1999

ImmunoGen reports positive preclinical data for TAP, intention to speed up development

Nov. 19, 1999

AnorMED's platinum-based cancer treatment enters phase I clinical trials

Nov. 19, 1999

AACR-NCI-EORTC meeting highlights: phase I data reported for Lilly cryptophycin analogue

Nov. 19, 1999

Tumor regressions, good safety reported for CCI-779 at international conference

Nov. 19, 1999

Takeda presents new series for androgen- or estrogen-dependent disorders

Nov. 19, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...